Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy

BACKGROUND: To analyze and compare the economic outcomes of adjuvant chemotherapy with capecitabine plus oxaliplatin (referred to as the XELOX strategy) and of S-1 (the S-1 strategy) for gastric cancer patients after D2 gastrectomy. METHODS: A Markov model was developed to simulate the lifetime dise...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Bin, Li, Te, Cai, Jian, Xu, Yuejuan, Zhao, Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4301844/
https://www.ncbi.nlm.nih.gov/pubmed/25526802
http://dx.doi.org/10.1186/1471-2407-14-984

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4301844/
https://www.ncbi.nlm.nih.gov/pubmed/25526802
http://dx.doi.org/10.1186/1471-2407-14-984

Ejemplares similares